New hope for CLL patients: umbralisib shows promise in early trial
NCT ID NCT04163718
First seen Jan 07, 2026 · Last updated Apr 24, 2026 · Updated 20 times
Summary
This study tested the experimental drug umbralisib in 12 people with chronic lymphocytic leukemia (CLL) who had not yet received treatment. The goal was to see how well the drug shrank or controlled the cancer and to check for side effects. The study was stopped early, but results showed some patients had a partial or complete response to the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.